IL2RA and neoplasm: Numerous preclinical studies have demonstrated that anti-IL-2Rα MAb administration can deplete or functionally inactivate TRegs in mice and can augment anti-tumor immunotherapy if delivered as a prophylactic prior to vaccination [30], [50], [58].